Loading company
MoonLake Immunotherapeutics
MLTX · Nasdaq · ·
Next earnings: November 4, 2026
$11.44-1.0%Sep 29 close
- 1M
- -23.7%
- 6M
- -32.4%
- 1Y
- +59.6%
- 5Y
- +14.4%
MLTX · Nasdaq · ·
Next earnings: November 4, 2026
$11.44-1.0%Sep 29 close
MoonLake Immunotherapeutics is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$61.8M | -$55.2M | -11.93% |
| Profit per share | -$0.84 | -$0.87 | +3.45% |
| Free Cash Flow | -$55.6M | -$54.5M | -1.89% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
MoonLake Immunotherapeutics has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Palmoplantar Pustulosis (PPP) is characterized by the development of blister-like pustules within erythematous, scaly plaques on the palms and the soles of the feet. PPP typically develops in adulthood and more frequently impacts females. Patients frequently experience significant pain, burning, and itching sensations on the palms and soles of the feet which can be debilitating and impair their ability to work, sleep, or perform other activities of daily living. Currently, the treatment of PPP is challenging with a significant unmet need for novel therapies to reduce the symptom burden for patients. Evidence suggests that activation of the IL-17 pathway has an important role in disease pathophysiology.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from MoonLake Immunotherapeutics’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.